NCT01594398 - Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

May 31, 2014

Conditions

Lung CancerNon Small Cell Lung Cancer (NSCLC)Breast CancerEstrogen Receptor Breast Cancer

Interventions

DRUG

entinostat

10 mg, po, q14 days, until progression or intolerable toxicity

DRUG

entinostat

10 mg, po, q14 days, until progression or intolerable toxicity

DRUG

Erlotinib

Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd.

DRUG

Erlotinib

Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd.

DRUG

Exemestane

Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.

DRUG

Exemestane

Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.

Trial Locations (3)

Florida Cancer Specialists, Sarasota

Sarah Cannon Research Institute, Nashville

Peggy and Charles Stephenson Cancer Center, Oklahoma City